Barrington Research Reiterates Outperform on Haemonetics, Maintains $105 Price Target
Portfolio Pulse from Benzinga Newsdesk
Barrington Research analyst Michael Petusky has reiterated an Outperform rating on Haemonetics (NYSE:HAE), maintaining a price target of $105.
February 13, 2024 | 2:32 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Barrington Research maintains an Outperform rating on Haemonetics with a $105 price target.
The reiteration of an Outperform rating and a maintained price target of $105 by a reputable analyst firm like Barrington Research is likely to instill confidence among investors and could lead to a positive short-term impact on Haemonetics' stock price. Analyst ratings and price targets are significant indicators for investors, and positive reaffirmations can drive investor sentiment and stock performance.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100